These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 26251034)

  • 21. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.
    Suzuki R; Orsini N; Saji S; Key TJ; Wolk A
    Int J Cancer; 2009 Feb; 124(3):698-712. PubMed ID: 18988226
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of chemoendocrine therapy in premenopausal and postmenopausal models with human breast cancer xenografts.
    Kataoka M; Yamaguchi Y; Moriya Y; Sawada N; Yasuno H; Kondoh K; Evans DB; Mori K; Hayashi S
    Oncol Rep; 2012 Feb; 27(2):303-10. PubMed ID: 22076074
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Gene expression signature of estrogen receptor alpha status in breast cancer.
    Abba MC; Hu Y; Sun H; Drake JA; Gaddis S; Baggerly K; Sahin A; Aldaz CM
    BMC Genomics; 2005 Mar; 6():37. PubMed ID: 15762987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A prospective study of plasma prolactin concentrations and risk of premenopausal and postmenopausal breast cancer.
    Tworoger SS; Eliassen AH; Sluss P; Hankinson SE
    J Clin Oncol; 2007 Apr; 25(12):1482-8. PubMed ID: 17372279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis.
    Vrieling A; Buck K; Kaaks R; Chang-Claude J
    Breast Cancer Res Treat; 2010 Oct; 123(3):641-9. PubMed ID: 20711809
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Methylation of estrogen receptor beta promoter correlates with loss of ER-beta expression in mammary carcinoma and is an early indication marker in premalignant lesions.
    Rody A; Holtrich U; Solbach C; Kourtis K; von Minckwitz G; Engels K; Kissler S; Gätje R; Karn T; Kaufmann M
    Endocr Relat Cancer; 2005 Dec; 12(4):903-16. PubMed ID: 16322330
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogens Correlate with PELP1 Expression in ER Positive Breast Cancer.
    Flågeng MH; Knappskog S; Gjerde J; Lønning PE; Mellgren G
    PLoS One; 2015; 10(8):e0134351. PubMed ID: 26247365
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adjuvant endocrine therapy in pre- versus postmenopausal patients with steroid hormone receptor-positive breast cancer: results from a large population-based cohort of a cancer registry.
    Inwald EC; Koller M; Klinkhammer-Schalke M; Zeman F; Hofstädter F; Lindberg P; Gerstenhauer M; Schüler S; Treeck O; Ortmann O
    J Cancer Res Clin Oncol; 2015 Dec; 141(12):2229-40. PubMed ID: 26253629
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Body mass index (BMI) and breast cancer: impact on tumor histopathologic features, cancer subtypes and recurrence rate in pre and postmenopausal women.
    Biglia N; Peano E; Sgandurra P; Moggio G; Pecchio S; Maggiorotto F; Sismondi P
    Gynecol Endocrinol; 2013 Mar; 29(3):263-7. PubMed ID: 23174088
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Early start of adjuvant chemotherapy may improve treatment outcome for premenopausal breast cancer patients with tumors not expressing estrogen receptors. The International Breast Cancer Study Group.
    Colleoni M; Bonetti M; Coates AS; Castiglione-Gertsch M; Gelber RD; Price K; Rudenstam CM; Lindtner J; Collins J; Thürlimann B; Holmberg S; Veronesi A; Marini G; Goldhirsch A
    J Clin Oncol; 2000 Feb; 18(3):584-90. PubMed ID: 10653873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome and global gene expression data support the existence of the estrogen receptor-negative/progesterone receptor-positive invasive breast cancer phenotype.
    Schroth W; Winter S; Büttner F; Goletz S; Faißt S; Brinkmann F; Saladores P; Heidemann E; Ott G; Gerteis A; Alscher MD; Dippon J; Schwab M; Brauch H; Fritz P
    Breast Cancer Res Treat; 2016 Jan; 155(1):85-97. PubMed ID: 26650824
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An ER-associated miRNA signature predicts prognosis in ER-positive breast cancer.
    Zhou X; Wang X; Huang Z; Xu L; Zhu W; Liu P
    J Exp Clin Cancer Res; 2014 Nov; 33(1):94. PubMed ID: 25373603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The oestrogen receptor coactivator CARM1 has an oncogenic effect and is associated with poor prognosis in breast cancer.
    Habashy HO; Rakha EA; Ellis IO; Powe DG
    Breast Cancer Res Treat; 2013 Jul; 140(2):307-16. PubMed ID: 23887673
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Estrogenic status influences nitric oxide-regulated TNF-alpha release from human peripheral blood monocytes.
    Schurman L; Sedlinsky C; Mangano A; Sen L; Leiderman S; Fernandez G; Theas S; Damilano S; Gurfinkel M; Seilicovich A
    Exp Clin Endocrinol Diabetes; 2001; 109(6):340-4. PubMed ID: 11571673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression.
    Anders CK; Hsu DS; Broadwater G; Acharya CR; Foekens JA; Zhang Y; Wang Y; Marcom PK; Marks JR; Febbo PG; Nevins JR; Potti A; Blackwell KL
    J Clin Oncol; 2008 Jul; 26(20):3324-30. PubMed ID: 18612148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Oligonucleotide microarray analysis of estrogen receptor alpha-positive postmenopausal breast carcinomas: identification of HRPAP20 and TIMELESS as outstanding candidate markers to predict the response to tamoxifen.
    Tozlu-Kara S; Roux V; Andrieu C; Vendrell J; Vacher S; Lazar V; Spyratos F; Tubiana-Hulin M; Cohen P; Dessen P; Lidereau R; Bièche I
    J Mol Endocrinol; 2007 Oct; 39(4):305-18. PubMed ID: 17909269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.